Travere Therapeutics (NASDAQ:TVTX) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.26) by 119.23 percent. This is a 126.32 percent increase over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $127.199 million which missed the analyst consensus estimate of $136.822 million by 7.03 percent. This is a 55.63 percent increase over sales of $81.732 million the same period last year.